AK104 + Lenvatinib
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hepatocellular Carcinoma
Conditions
Hepatocellular Carcinoma
Trial Timeline
Aug 2, 2024 → May 23, 2026
NCT ID
NCT06371157About AK104 + Lenvatinib
AK104 + Lenvatinib is a phase 3 stage product being developed by Akeso for Hepatocellular Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06371157. Target conditions include Hepatocellular Carcinoma.
What happened to similar drugs?
5 of 20 similar drugs in Hepatocellular Carcinoma were approved
Approved (5) Terminated (2) Active (14)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06371157 | Phase 3 | Recruiting |
| NCT05319431 | Phase 2 | Active |
| NCT04444167 | Phase 1/2 | Completed |
Competing Products
20 competing products in Hepatocellular Carcinoma